Osang Healthcare to Supply HbA1c Analyzers to Mexican Government on a Large Scale

Osang Healthcare, a company specializing in in vitro diagnostics, announced on May 13 that it will supply its HbA1c analyzer, the "HemoCue® HbA1c 501 System," to the large-scale public healthcare procurement market of the Mexican government through HemoCue AB. HemoCue AB, a subsidiary of Danaher, is a leading company in the field of point-of-care diagnostic solutions.

HemoCue recently received the final award notification for the HbA1c analyzer from the main public healthcare procurement agency under the Mexican Ministry of Health. Osang Healthcare has received a purchase order (PO) worth approximately 4.39 million dollars (about 6.5 billion won) from HemoCue and has disclosed the signing of an exclusive sales and supply contract. The company plans to provide additional devices and cartridges over the next two years.

This contract was awarded as a result of a comprehensive evaluation of the product's technological capabilities and cost competitiveness. Key strengths included its wide measurement range, high accuracy, convenience of cartridge storage at room temperature, and a strict quality control system. The product will be supplied to medical sites across Mexico, and as major national medical institutions such as IMSS Bienestar participate, brand recognition is expected to expand throughout Latin America.

An Osang Healthcare representative stated, "This project is an example that demonstrates our technological strength and global supply capabilities," adding, "We aim to maintain our competitive edge in upcoming bids through reliable supply."

This content was produced with the assistance of AI translation services.